SOURCE: IBC Life Sciences

August 09, 2005 08:17 ET

New Cases of "Mad Cow" Disease Drive Efforts to Confront Potential Problems

Conference Corrals Scientists to Exchange Strategies to Detect and Control Ineffectivity in Biopharmaceuticals

WESTBOROUGH, MA -- (MARKET WIRE) -- August 9, 2005 -- In June 2005, a cow in the United States was proven to have "mad cow disease" or Bovine Spongiform Encephalopathy (BSE). Concerns among biopharmaceutical companies using bovine serum in cell culture media or manufacturing blood and tissue products remain.

Scientists will gather at the IBC Life Sciences Second Annual Transmissible Spongiform Encephalopathies (TSE) conference to examine information needed for the development of risk assessment plans and control procedures. The conference is set for November 16-17, 2005 at the Hyatt Regency in Reston, Virginia.

The conference features scientific updates on prion proteins and strategies to help industry executives track progress on the development of diagnostic tests to improve the quality and cost of monitoring TSE infectivity. Presentations reveal industry best practices, case studies from leading researchers and FDA regulatory updates to help assess readiness to confront potential problems. Conference highlights include:

--  How to control prion activity in biopharmaceutical manufacturing
    environments
    
--  New understandings of the etiology and properties of TSEs
    
--  Tracking TSEs: Current updates on the international incidence of BSE
    and vCJD
    
--  Progress in the development of accurate and reproducible ante-mortem
    screening assays
    
--  United States and European Union regulatory updates and their impact
    on production environments
    
The TSE conference is co-located with IBC's 7th International Viral Safety and 8th Annual Well Characterized Biologicals set for November 14-15 also at the Hyatt Regency. Presentations from Viral Safety and Well Characterized Biologials examine proven characterization and validation techniques to help achieve the fastest possible regulatory approval. The complete agenda is available online at http://www.ibclifesciences.com/wcb.

To receive a press pass for this event or to arrange an interview with a speaker, contact Andrew White at (508) 616-5550, x227.

About IBC Life Sciences

IBC Life Sciences is an independent organizer that is in business to provide an unbiased forum for the evaluation of current research, market trends, technological developments and applications. IBC Life Sciences is part of IBC USA Conferences, Inc., a division of T&F Informa plc (London: TFI). T&F Informa was created through the merger of Informa Group plc and Taylor & Francis Group plc in May 2004. The two companies are market leaders in providing specialist information to commercial and academic markets through conferences and trade events, as well as the publication of academic, scientific and professional books, journals and newsletters.

To download the TSE brochure, visit: http://www.IBCLifeSciences.com/TSE

Contact Information

  • Contact:
    Andrew White
    IBC Life Sciences
    (508) 616-5550 Ext. 227
    Email Contact